Q2055 Idecabtagene vicleucel - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Idecabtagene vicleucel

Brand Name:

Abecma

Strength:

460 million

HCPCS:

Q2055

SEER*Rx Category:

Immunotherapy

Major Drug Class:

CAR-T

Minor Drug Class:

BCMA

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

Jan. 26, 2022

CMS Discontinuation Date:

Status:

In Use